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Abstract
Background: Poor sleep is a frequent symptom in patients with multiple sclerosis (MS). Sleep may be influenced by MS-
related symptoms and adverse effects from immunotherapy and symptomatic medications. We aimed to study the
prevalence of poor sleep and the influence of socio-demographic and clinical factors on sleep quality in MS- patients.
Methods: A total of 90 MS patients and 108 sex-and age- matched controls were included in a questionnaire survey. Sleep
complaints were evaluated by Pittsburgh Sleep Quality Index (PSQI) and a global PSQI score was used to separate good
sleepers (#5) from poor sleepers (.5). Excessive daytime sleepiness, the use of immunotherapy and antidepressant drugs,
symptoms of pain, depression, fatigue and MS-specific health related quality of life were registered. Results were compared
between patients and controls and between good and poor sleepers among MS patients.
Results: MS patients reported a higher mean global PSQI score than controls (8.6 vs. 6.3, p = 0.001), and 67.1% of the MS
patients compared to 43.9% of the controls (p = 0.002) were poor sleepers. Pain (p = 0.02), fatigue (p = 0.001), depression
(p = 0.01) and female gender (p = 0.04) were associated with sleep disturbance. Multivariate analyses showed that female
gender (p = 0.02), use of immunotherapy (p = 005) and a high psychological burden of MS (p = 0.001) were associated with
poor sleep among MS patients.
Conclusions: Poor sleep is common in patients with MS. Early identification and treatment of modifiable risk factors may
improve sleep and quality of life in MS.
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Introduction
Patients with multiple sclerosis (MS) frequently report poor
sleep, and sleep disorders are more common in MS patients
compared to healthy controls [1]. Causes of poor sleep in MS are
likely multifactorial, and potential triggers may relate to adverse
effects from immunotherapy and symptomatic medications and to
MS-associated symptoms, such as pain and fatigue [2]. Certain
symptoms related to MS, may lead to exacerbation of others if left
untreated [3]. Patients suffering from a sleep disturbance have an
increased risk of developing co-morbid conditions like heart
disease, obesity and diabetes that may have a profound impact on
long-term health [4,5]. In order to improve sleep and possibly
reduce long-term health consequences of poor sleep in MS,
identification of modifying risk factors of poor sleep is needed.
Therefore we aimed to study the prevalence of sleep disturbance in
MS, compared to the healthy Norwegian population. Further,
among MS-patients, we aimed to identify possible socio-demo-
graphic and clinical factors associated with the risk of being a poor
sleeper. Two prior studies have described the socio-demographic
and clinical factors associated with poor sleep, both lacking a
control group for comparisons [1,6]. To our knowledge, a case-
control study looking at the socio-demographic and clinical




The study was based on written informed consent, and
approved by the Regional Committee for Medical and Health
Research Ethics of Western Norway.
Patients and controls
We aimed to include patients’ with well-established disease. All
140 patients diagnosed with MS from 1993–1998 at the
Department of Neurology, Haukeland University Hospital,
Bergen, Norway were invited to participate in the study. All
MS-patients fulfilling the diagnostic criteria of Poser were
included, independent of subtype. The patients were identified
though hospital records and recruited at the Department of
Neurology, Haukeland University Hospital. A total of 280 age-
and gender-matched controls were drawn from the Norwegian
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National Population Registry. There were no exclusion criteria.
The data were collected by use of validated self-administered
questionnaires and returned by mail in pre-stamped addressed
return envelopes. All participants received the same set of study
information and questionnaires, except for the MSIS-29 question-
naire, specifically designed for MS patients. A reminder was sent
to each non-respondent participant via the mail two months after
the initial questionnaires were mailed out. The collected data from
the questionnaires were registered and entered in a database that
was carefully double and triple checked for any mistakes in data
entry.
Variables
Age, gender, marital status and the use of medication were
registered. The regular medications were recorded and grouped
into three classes: antidepressant drugs, immunotherapy and
others. The questionnaires used are all validated, and all but the
VAS pain scale are also validated in Norwegian [7–11].
Pittsburgh Sleep Quality Index (PSQI) was included to measure
sleep and identify sleep complaints during the previous month
[12]. It has several clinical and research applications and can be
used to separate ‘‘good’’ from ‘‘poor’’ sleepers, screen for night
time sleep disturbances and to monitor the progression of sleep
disorders [13,14]. However, it cannot be used to diagnose specific
sleep disorders and does not provide information on sleep stages or
sleep architecture that can be measured by polysomnography
(PSG) [15]. It consists of 19 self- rated questionnaires and 5
additional questionnaires for bed partner.
It provides a global score of sleep on a scale from 1 to 21, with
higher scores indicating more sleep complaints. A global PSQI
score .5 is shown to have a diagnostic sensitivity of 89.6% and a
specificity of 86.5% and was used to separate good sleepers (#5)
from poor sleepers (.5) [12]. Test-retest reliability has shown
consistency over time [16].MS-specific health related quality of life
was recorded by the Multiple Sclerosis Impact Scale (MSIS-29),
that includes the physical (20 items) and psychological (9 items)
impact of MS. High scores on MSIS-29 indicate greater impact of
MS. Naturally, only MS patients answered these questions, and
associations to poor sleep was analysed separately for the
physiological and psychological subscales of MSIS-29 (Hobert J)
[17].
Excessive daytime sleepiness was registered by the Epworth
sleepiness scale (ESS), that is a validated and widely used self-
administered questionnaire used to investigate excessive daytime
sleepiness/hypersomnia [18]. It can be used as a screening test for
excessive sleepiness or longitudinally to follow a patient’s response
to an intervention. It measures the proneness to fall asleep or doze
off in eight specific situations. An ESS score above 10 is regarded
as an indicator of excessive sleepiness.
We assessed acute pain by using the validated Visual Analogue
Scale for pain assessment. The VAS pain scale consists of a 10 cm
(3.94 inches) line with one end labelled ‘‘no pain’’ and the other
end labelled ‘‘worst imaginable pain ever’’. The participants were
asked to mark the line at the point that best described the pain
intensity. For qualitative analysis we separated the data in two
groups ‘‘no pain (0–1 points)’’ and ‘‘pain (.1 point) [19]. The
presence of pain at the time of completing the questionnaire was
registered as present or not [20].
Fatigue was registered by the Fatigue Questionnaire (FQ) that is
a validated questionnaire used to assess fatigue severity. It is an 11
item questionnaire used to measure physical and mental fatigue
during the previous month (scale 0–3) with a cut off score at 4
considered indicative of excessive fatigue [21].
Symptoms of depression were screened by the Beck Depression
Inventory (BDI–II) that includes 21-question self-reporting mul-
tiple choice questions. The patients BDI score was categorized as
not depressed (score 0–19) and depressed (score.20) [11,22].
Statistical analysis
Socio-demographic variables (age, gender, and marital status),
medication, and clinical characteristics as well as the seven
components of the PSQI questionnaire were compared between
patients and controls. Among MS patients, the same variables in
addition to health related quality of life (MSIS-29) was compared
between good- and poor sleepers.
The Fischer Exact Test was applied to compare groups for
nominal variables. The Mantel-Haenszel test was used for ordinal
variables and independent two sample t- test was applied for
continuous variables. Normal distribution and equality of variance
was checked before applying the parametric t-test. Crude p-values
are reported.
Independent two sample t- test was applied for continuous
variables. Normal distribution and equality of variance was
checked before applying the parametric t-test. Crude p-values
are reported.
An analysis was performed to identify factors associated with
poor sleep. Logistic regression was performed to estimate odds
ratios, first in univariate models until a multivariate model was
fitted. Variables with univariate P,0.25 were selected as
candidates in the multivariate analysis following a model-building
strategy as described by Hosmer & Lemeshow [23].
Data analyses were carried out using SPSS software for
Windows (version 15.0, SPSS, Chicago IL), p-values ,0.05 were
considered statistically significant.
Results
Comparisons of patients and controls
A total of 90 MS patients (64.3%) and 108 (38.6%) control
persons responded to the invitation to participate in the survey.
Socio-demographic characteristics and the use of antidepressant
drugs did not differ significantly among patients and controls
(Table 1). The average age of the patients were 45610.4 and the
controls were 44.3610.2 (p = 0.65). Of the patients, 41(45.6%)
were men and 49 (54.4%) were women, and 45(41.7%) men and
63(58.3%) women made up the control group (p = 0.667) (Table 1).
The mean score of excessive daytime sleepiness (ESS) did not differ
between patients and controls and mean values were below cut-off
for excessive sleepiness (data not shown). Pain (p = 0.01), fatigue
(p = 0.004) and depression (p = 0.02) were reported more fre-
quently among patients than controls. Thirty-five (42.7%) patients
received immunotherapy (interferon beta (n = 24), glatiramer
acetate (n = 7), natalizumab (n = 2)) (Table 1). MS patients had a
significantly higher mean global PSQI score (8.664.6) compared
to controls (6.364.1), indicating a poorer sleep quality (p = 0.001)
(Table 2). PSQI sleep onset latency was significantly higher
(1.461.1) among patients than controls (1.161.1) (0.04) (Table 2).
The proportion of MS patients (67.1%) that reported poor quality
of sleep was significantly higher than the controls (43.9%)
(p = 0.002).
Risk factors associated with poor sleep among patients
with MS
More women (78.0%) than men (53.1%) suffered from poor
sleep among the MS patients (p = 0.04). Further, pain (p = 0.02)
and fatigue (p = 0.001) were associated with higher risk for being a
poor sleeper (Table 3). All patients classified with moderate
Poor Sleep in MS
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depression (p = 0.01) and all patients on antidepressant medica-
tions suffered from poor sleep (p = 0.03). Excessive daytime
sleepiness was not significantly associated with poor sleep among
patients (p = 0.12) (Table 3). Higher score on mean MSIS-29
physiological and psychological sub scores, were associated with
higher risk of being a poor sleeper (p,0.001).
Multivariate logistical regression analyses showed that female
gender, (OR = 6.8, 95% CI: 1.33–35.3), immunotherapy
(OR = 4.7, 95% CI: 0.98–23.3) and reduced quality of life
(MSIS-29 psychological subscale) (OR = 1.12, 95% CI: 1.05–
1.19) were associated with poor sleep (Table 4).
Discussion
Poor sleep is a common finding in MS patients, and previous
studies have indicated a prevalence of 50% in this patient group
[24,25]. In the present survey, we report a higher frequency of MS
patients (67.1%) with disturbed sleep. The focus of this study was
to disclose potential modifiable clinical and socio-demographic
(age, gender, marital status) risk factors associated with sleep
disturbance in MS patients. Among demographic variables that
were associated with sleep disturbance, female gender was found
to be strongly associated with poor sleep. This is in contrast to a
previous study that reported no influence of gender on sleep
quality among MS patients [1].
Psychiatric disorders, and especially depression, are prevalent in
MS and have major impact on quality of life [26].We found a 3-
fold higher prevalence of depressive symptoms among patients
compared to controls, consistent with the results of a previous
study [27]. All patients classified as having moderate depression in
our study suffered from poor sleep. Insomnia and depression are
closely linked, and appear to have a bidirectional relationship
where insomnia worsens depression and vice versa [28,29]. MS
patients reporting poor sleep should therefore be screened for
depression, and treated accordingly.
Table 1. Clinical and socio-demographic parameters among
patients and controls.
Variable Patients Controls p-value
N = 90* N = 108**
Age, yrs (mean6SD) 45.0610.4 44.3610.2 0.65
Gender (female; %) 54.4 58.3 0.67
Married (%) 58.5 66.7 0.29
Antidepressant drugs (%) 9.8 3.7 0.08
Immunotherapy (%) 42.7 1.9 ,0.001
Excessive daytime sleepiness (ESS) (%) 33.8 22.6 0.10
Pain (VAS) (%) 38.8 21.3 0.01
Fatigue (FQ) (%) 35.5 15.8 0.004
Depression (BDI) (%) 15.8 4.2 0.02
MSIS-29 physiological disease severity 27.4624.7 NA -
MSIS-29 psychological disease severity 28.1625.1 NA -
ESS = Epworth Sleepiness Scale; FQ = Fatigue Questionnaire; BDI = Beck.
Depression Inventory; MSIS-29 = Multiple Sclerosis Impact Scale.
*Number of patients range from 76–90;
**Number of controls range from 96–108. Immunotherapy (IFNB, glatiramer
acetate, natalizumab).
doi:10.1371/journal.pone.0049996.t001
Table 2. Pittsburgh Sleep Quality Index (PSQI) scores among
patients and controls.
Variable* Patients Controls p-value
N = 90** N = 108***
PSQI global score 8.664.6 6.364.1 0.001
PSQI sleep quality 1.160.7 0.960.8 0.03
PSQI sleep onset latency 1.461.1 1.161.1 0.04
PSQI sleep duration 0.960.8 0.860.7 0.39
PSQI sleep efficiency 0.761.0 0.560.8 0.10
PSQI sleep disturbance 1.460.6 1.360.6 0.33
PSQI hypnotic drugs 0.761.2 0.360.8 0.005
PSQI daytime dysfunction 1.360.8 0.860.7 ,0.001
*Data are displayed as mean standard deviation;
**Number of patients range from 76–90;
***Number of controls range from 96–108.
doi:10.1371/journal.pone.0049996.t002
Table 3. Comparisons of clinical and socio-demographic







Age, Mean6SD 43.2612.0 46.2610.4 0.27
Gender, n (%) 0.04
Female 9 (22.0) 32 (78.0)
Male 15 (46.9) 17 (53.1)
Married, n (%) 0.80
No 11 (35.5) 20 (64.5)
Yes 13 (31.0) 29 (69.0)
Antidepressant drugs, n (%) 0.047
No 24 (36.9) 41 (63.1)
Yes 0 (0.0) 8 (100)
Immunotherapy, n (%) 0.21
No 17 (39.5) 26 (60.5)
Yes 7 (23.3) 23 (76.7)
ESS, n (%) 0.12
0–10 18 (39.1) 28 (60.9)
Above 10 5 (20.0) 20 (80.0)
Pain, n (%) 0.02
No 19 (44.2) 24 (55.8)
Yes 5 (17.2) 24 (82.8)
Fatigue (FQ), n (%) 0.001
0–4 21 (46.7) 24 (53.3)
Above 4 2 (8.0) 23 (92.0)
Depression (BDI II), n (%) 0.01
0–19 23 (39.7) 35 (60.3)
Above 19 0 (0.0) 10 (100)
MSIS-29 physiological, Mean6SD 10.5613.9 34.9622.1 ,0.001
MSIS-29 psychological, Mean6SD 9.4612.9 38.0622.6 ,0.001
MSIS-29: Multiple Sclerosis Impact Scale. ESS: Excessive daytime sleepiness.
FQ: Fatigue questionnaire, BDI: Beck Depression Inventory.
doi:10.1371/journal.pone.0049996.t003
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Subjective sleep disorders in MS and in the general population
have in numerous epidemiological studies showed a close a close
association with symptoms of fatigue [1,30,31]. Sleep disturbance
has been reported as a significant independent contributor to
fatigue in MS, and in our study, as many as 92% of the patients
suffering from fatigue was classified as poor sleepers. A recent
randomized controlled therapy study revealed improvement in
fatigue by treatment of sleep disorders in MS [32]. However, the
pathophysiology of MS-related fatigue is poorly understood and
the cause and effect relationship between disturbed sleep and MS-
related fatigue is currently an enigma.
Poor quality of sleep in MS patients was not associated with
excessive daytime sleepiness, despite increased frequencies of
fatigue and sleep complaints in patients categorized as poor
sleepers. These results are compatible with a pupillographic and
questionnaire (ESS,SSS) study of 61 MS patients, that reported no
evidence of excessive daytime sleepiness in MS [33]. Symptoms of
fatigue and sleepiness in MS patients are often confused and used
interchangeably [34]. Subjective sleepiness and subjective fatigue
in MS patients and healthy controls have shown to be
independently associated with sleep disorders, although correlated
with each other [34]. Patients with insomnia often complain of
fatigue, but not sleepiness or the propensity to fall asleep [34].
These studies suggest that fatigue and excessive daytime sleepiness
are differentiated conditions and should be assessed independently
in patients complaining of poor sleep.
Acute and chronic pain is a frequent symptom in MS, and
include neuropathic pain and musculoskeletal pain secondary to
other MS symptoms such as spasticity [35]. Population studies
have estimated that 55–65% of MS patients suffer from acute,
subacute or chronic pain syndrome [36]. We found that the
presence of pain was reported about twice as frequent among MS-
patients compared to controls. Pain was also significantly more
frequent in poor sleepers than in good sleepers. Similar findings
was reported in a previous study, that in addition found pain to be
the main cause of initial insomnia [37]. In an epidemiologic study
of women with RRMS, sleep disturbance intensity were higher for
women with RRMS with pain than for women without pain [38].
Pain is a common, but often inadequately treated symptom in MS
[39]. By modifying pain, improved sleep may be obtained.
Separate analyses of each PSQI component showed that
increased sleep latency was the most frequent complaint among
MS patients, followed by sleep disturbance and daytime dysfunc-
tion. This was in line with a previous study, where initial insomnia
was rated as the most common complaint of the PSQI component
values [1].
No significant differences were noted between patients and
controls regarding sleep disturbance and sleep efficiency.
The results from our study reveal that the psychological and
physiological impact of MS is greater among poor sleepers than
among good sleepers. In our study a high psychological burden of
MS was independently associated with poor sleep. Nearly half of
MS patients have reported significant anxiety levels within the first
year of diagnosis [40]. Traditionally, management of MS have
focused primarily on treatment of motor symptoms [41].
Treatment of non-motor symptoms such as psychological impact
of MS is usually associated with improvement of HRQoL [41].
Sleep disruption evident by polygraphic registration is associated
with greater psychological impact on quality of life [42]. More
emphasis on the relief of psychological distress of MS may likely
favour good sleep.
In this study, the use of immunotherapy was independently
associated with poor quality of sleep. An actigraphy study of
relapsing-remitting MS patients using immunomodulatory (inter-
feron beta, glatirmaer acetate) drugs, showed a reduction in sleep
efficiency in two-thirds on the night following interferon beta
injection, irrespective of the frequency of injections [43]. Another
study recently reported reduced flu-like symptoms and improved
sleep efficacy by switching from evening to morning injections of
interferon beta [44].
It is a usual recommendation from neurologists, that interferon
beta should be injected in the evening, so that the patient can sleep
through the side-effects [45]. We have systematically advised
patients to take evening injections of IFNB. Although our results
reveal no causality between use of immunotherapy and poor sleep,
we believe however, that our findings are sufficiently suggestive to
introduce a possible theory on the relationship between timing of
immunomodulatory drugs and impact on sleep. The possibility
that improved sleep may be obtained by changing administration
time of immunomodulatory medication, is important in regards to
sleep management, and further studies should be warranted in this
regard.
There are several limitations in our study. As this is a cross
sectional study, we cannot determine the directions of the
predictors of poor sleep. We can only show significant clinical
and demographic associations to poor sleep quality. The lower
response rate in the control group can be explained by the
collection of information by mail, and by a set of questionnaires
that was comprehensive and time demanding. Controls suffering
from poor sleep may have had particular interest in this subject;
this may have skewed the data towards smaller differences between
patients and controls.
Micturition-related symptoms such as urge and nocturia were
not analysed separately, as these parameters were included in the
sleep quality component of MSIS -29 and PSQI respectively.
Furthermore, the pain assessment was limited and multidimen-
sional measures such as McGill Pain Questionnaire or Multidi-
mensional pain inventory, would possibly have added more
information. The expanded disability scale (EDSS) was not
assessed, and therefore a possible relationship between disability
status and sleep disturbance could not be established.
The results of this study indicate that poor sleep is a frequent
complaint among patients with MS and independently associated
with female gender, use of immunotherapy and a high psycho-
logical burden of MS. Sleep disturbance is a potentially treatable
condition. Increased awareness of modifiable risk factors of poor
sleep in MS may be important for early therapeutic and
prophylactic interventions.
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